Skip to main content

Russia to supply Avifavir drug to 17 nations for Coronavirus Treatment

By Unknown

The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group have agreed to supply Avifavir, the world's first registered favipiravir-based drug against coronavirus and Russia’s first drug approved for the treatment of COVID-19, to 17 countries.

Avifavir and other favipiravir-based drugs produced in Russia, as well as Remdesivir developed in the US are currently the leading drugs against COVID-19registered globally.

Avifavir will be delivered to Argentina, Bulgaria, Brazil, Chile, Colombia, Ecuador, El Salvador, Honduras, Kuwait, Panama, Paraguay, Saudi Arabia, Serbia, Slovakia,South Africa, UAE and Uruguay.

The drug has already been delivered to Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan.

On May 29, 2020, Avifavir received a registration certificate from Russia’s Ministry of Health based on thorough and transparent clinical data and became the first favipiravir-based drug in the world approved for the treatment of COVID-19. Approximately five months after the clinical trials of Avifavir in Russia, the efficacy of favipiravir against the novel coronavirus infection was confirmed by Japan’s Fujifilm. On September 23, 2020, the company announced that according to the results of its Phase III clinical trial, the administration of its favipiravir-based drug Avigan to 156 patients demonstrated shorter time to resolution as compared with the placebo group.

The efficacy of Avifavir has been demonstrated in clinical trials which significantly exceed in scale those conducted by other Russian manufacturers of favipiravir. These trials have been conducted in full compliance with international standards and the requirements of regulatory authorities around the world. Since April, 408patients with confirmed coronavirus have participated in the studies at 35 medical centers across Russia. In October the number of patients will increase to 460.

Since June 2020, more than 60,000 packages of Avifavir have been delivered to clinics in 74 Russian regions. Since the start of Avifavir supplies, clinical monitoring has been carried out based on data from the register of patients with coronavirus of the Ministry of Health of Russia. Data on the use of Avifavir has been collected, with further analysis as well as scientific and medical assessmentconducted. According to the results of the observational post-registration clinical trial of 940 patients, those taking Avifavir demonstrated elimination of the virus at an earlier stage in 30% of the cases and the level of oxygen saturation was restored to normal twice as quickly compared with standard therapy (within two days versus four days). According to the results of the research, the drug is well tolerated, with no new adverse events identified.

Avifavir is now the leading Russian anti-COVID drug in terms of exports. In particular, the start of deliveries to Bolivia and other countries in Latin America was announced on September 21 as part of the agreement to deliver 150,000 packs. Avifavir has also been approved by regulators in Europe, Middle East and Asia.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said, “When we registered the first anti-coronavirus drug in the world based on favipiravir there was a lot of skepticism as people were wondering how we could register it when Japan had not registered it yet. Now five months after our clinical trials we see that Japan has confirmed the clinical efficacy of favipiravir. Avifavirhas been tested in more than 1,300 patients including 408 patients in clinical trials and 940 patients during the observational post-registration clinical trial.”

“We havenow conducted the largest clinical trial of a favipiravir-based drug against coronavirus in the world and can confirm its high efficacy. Since June, more than 60,000 packages of Avifavir have been delivered to clinics in 74 Russian regionsandnd more than 15 countries have confirmed their interest in the drug. Based on our extensive clinical trials and the research in Japan confirming favipiravir’sefficacy against coronavirus we believe that Avifavir and other favipiravir-based products will be the leading antiviral medicines against COVID-19 in the world. In addition to proven efficacy and safety Avifavir is also three to four times cheaper than Remdesivir."

RDIF is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.9 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn.

ChemRar Group unites R&D service and investment companies in the field of innovative pharmaceuticals for the development and commercialization of innovative medicines, diagnostics, preventive care and new treatments of life-threatening diseases in Russia and abroad


Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

Strictly Adhere to COVID-19 Regulations During Festivals, Mamata Banerjee Urges People

By Unknown
Banerjee, who was speaking after a cabinet meeting, said I ask everybody to follow the COVID-19 safety protocols during the festive season. There are instance of community transmission of novel coronavirus and also the contagion becoming air-borne. West bengal Chief Minister Mamata Banerjee on Monday urged people to strictly adhere to the COVID-19 regulations during the upcoming festive season as there are instances of the virus becoming air-borne and community transmission of the contagion in the state.  Banerjee, who was speaking after a cabinet meeting, said "I ask everybody to follow the COVID-19 safety protocols during the festive season. There are instance of community transmission of novel coronavirus and also the contagion becoming air-borne."  "I request Durga Puja Committees to not allow people without masks in pandals. They should be kept in a separate zone. If puja committees can give masks then it's fine. But we can't expect everyone to do the same,...
Post a Comment
Read more

Australia's Victoria state to ease COVID-19 restrictions as cases slow

By Unknown
Victoria, Australia's second most populous state and the epicentre of the country's COVID-19 outbreak, will accelerate the easing of social distancing restrictions as infections slow to fewer than 20 cases a day, its premier said on Sunday. Victoria, which reported 16 COVID-19 cases in the past 24 hours, has placed nearly 5 million residents of its capital Melbourne under one of the world's most stringent lockdowns since early August. With cases well below the record one-day high of more than 700 cases reported in August, state Premier Daniel Andrews said some curbs, including a night curfew, will be removed almost immediately. The remaining curbs could be relaxed earlier, with restrictions eased when case numbers hit certain triggers. Victoria state previously said most restrictions would remain in place until the end of November. "We are ahead of schedule, we have made more progress than we hoped to make at this point in time," Andrews told reporters in Melbou...
Post a Comment
Read more